A stabilised GHRH(1-44) analog bearing an N-terminal hexenoyl group that resists DPP-4 degradation. Stimulates pituitary GH release, raising IGF-1 and preferentially reducing visceral adipose tissue.
The only GHRH analog with a modern FDA approval. Phase 3 trials demonstrated visceral adipose tissue reduction in HIV-associated lipodystrophy. Studied subsequently in NAFLD in HIV populations.
FDA-approved — narrowly — for reduction of excess abdominal fat in HIV-associated lipodystrophy. Prescription-only. Approval does not extend to general body composition or anti-ageing use.
Raises IGF-1; label cautions around malignancy risk given GH-axis stimulation. Contraindicated in pregnancy and active malignancy. Injection-site reactions, arthralgia, oedema. Prohibited in sport (WADA S2).
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.